Some non-criteria aPLs can be applied as potential biomarkers to predict the risk of thrombosis in APS, such as anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT IgG/IgA/IgM), phosphatidylserine antibodies (aPS IgG) and antibodies directed against phospholipids, anexin V (17, 59, 60). The gene discussed is F2; the disease is autoimmune polyendocrinopathy.